Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||€127.50|
|52 Week High||€38.26|
|52 Week Low||€141.40|
|1 Month Change||-2.89%|
|3 Month Change||17.19%|
|1 Year Change||195.28%|
|3 Year Change||1,008.70%|
|5 Year Change||2,309.07%|
|Change since IPO||1,956.45%|
Recent News & Updates
Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Deserve Your Attention Today
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Have The Makings Of A Multi-Bagger
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...
Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Is An Interesting Stock
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
|EUZ||DE Medical Equipment||DE Market|
Return vs Industry: EUZ exceeded the German Medical Equipment industry which returned 56.6% over the past year.
Return vs Market: EUZ exceeded the German Market which returned 24.7% over the past year.
Stable Share Price: EUZ is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: EUZ's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates through two segments, Medical and Isotope Products. The Medical segment offers small radioactive implants for the treatment of prostate cancer seeds; and eye application based on ruthenium-106 or iodine-125 for treating uveal melanoma.
Eckert & Ziegler Strahlen- und Medizintechnik Fundamentals Summary
|EUZ fundamental statistics|
Is EUZ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EUZ income statement (TTM)|
|Cost of Revenue||€88.32m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 09, 2021
|Earnings per share (EPS)||1.56|
|Net Profit Margin||17.83%|
How did EUZ perform over the long term?See historical performance and comparison
0.4%Current Dividend Yield
Is Eckert & Ziegler Strahlen- und Medizintechnik undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: EUZ (€127.5) is trading above our estimate of fair value (€66.17)
Significantly Below Fair Value: EUZ is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: EUZ is poor value based on its PE Ratio (81.5x) compared to the German Medical Equipment industry average (28.1x).
PE vs Market: EUZ is poor value based on its PE Ratio (81.5x) compared to the German market (22.8x).
Price to Earnings Growth Ratio
PEG Ratio: EUZ is poor value based on its PEG Ratio (3x)
Price to Book Ratio
PB vs Industry: EUZ is overvalued based on its PB Ratio (15.4x) compared to the DE Medical Equipment industry average (4.3x).
How is Eckert & Ziegler Strahlen- und Medizintechnik forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EUZ's forecast earnings growth (26.7% per year) is above the savings rate (-0.01%).
Earnings vs Market: EUZ's earnings (26.7% per year) are forecast to grow faster than the German market (12.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EUZ's revenue (19.3% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: EUZ's revenue (19.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EUZ's Return on Equity is forecast to be high in 3 years time (21.9%)
How has Eckert & Ziegler Strahlen- und Medizintechnik performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EUZ has high quality earnings.
Growing Profit Margin: EUZ's current net profit margins (17.8%) are higher than last year (12.5%).
Past Earnings Growth Analysis
Earnings Trend: EUZ's earnings have grown significantly by 24.3% per year over the past 5 years.
Accelerating Growth: EUZ's earnings growth over the past year (50.1%) exceeds its 5-year average (24.3% per year).
Earnings vs Industry: EUZ earnings growth over the past year (50.1%) underperformed the Medical Equipment industry 92.9%.
Return on Equity
High ROE: EUZ's Return on Equity (18.4%) is considered low.
How is Eckert & Ziegler Strahlen- und Medizintechnik's financial position?
Financial Position Analysis
Short Term Liabilities: EUZ's short term assets (€166.8M) exceed its short term liabilities (€46.4M).
Long Term Liabilities: EUZ's short term assets (€166.8M) exceed its long term liabilities (€97.7M).
Debt to Equity History and Analysis
Debt Level: EUZ is debt free.
Reducing Debt: EUZ has no debt compared to 5 years ago when its debt to equity ratio was 13.2%.
Debt Coverage: EUZ has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: EUZ has no debt, therefore coverage of interest payments is not a concern.
What is Eckert & Ziegler Strahlen- und Medizintechnik current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: EUZ's dividend (0.35%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1%).
High Dividend: EUZ's dividend (0.35%) is low compared to the top 25% of dividend payers in the German market (3.24%).
Stability and Growth of Payments
Stable Dividend: EUZ is not paying a notable dividend for the German market, therefore no need to check if payments are stable.
Growing Dividend: EUZ is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: EUZ is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EUZ's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andreas Eckert (61 yo)
Dr. Andreas Eckert, PhD, is the Founder and Managing Partner of ELSA Eckert Life Science Accelerator GmbH. Dr. Exkert is the Founder of Eckert & Ziegler Strahlen & Medizintechnik AG and serves as its Chief...
CEO Compensation Analysis
Compensation vs Market: Andreas's total compensation ($USD1.14M) is below average for companies of similar size in the German market ($USD1.88M).
Compensation vs Earnings: Andreas's compensation has been consistent with company performance over the past year.
Experienced Management: EUZ's management team is seasoned and experienced (6.3 years average tenure).
Experienced Board: EUZ's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Eckert & Ziegler Strahlen- und Medizintechnik AG's employee growth, exchange listings and data sources
- Name: Eckert & Ziegler Strahlen- und Medizintechnik AG
- Ticker: EUZ
- Exchange: XTRA
- Founded: 1992
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €2.610b
- Shares outstanding: 20.75m
- Website: https://www.ezag.com
Number of Employees
- Eckert & Ziegler Strahlen- und Medizintechnik AG
- Robert-Rössle-Strasse 10
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 20:52|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.